RESEARCH TRIANGLE PARK, NORTH CAROLINA -- (MARKET WIRE) -- March 08, 2007 -- Adherex Technologies Inc. (TSX: AHX)(AMEX: ADH), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced that Dr. Antonella Perotti, MD, Istituto Nazionale dei Tumori Milano, SENDO Foundation, an investigator in Adherex's European Phase Ib/II study of single-agent ADH-1, will present data today from that study at the 5th International Symposium on Targeted Anticancer Therapies in Amsterdam, The Netherlands.
